About Shanghai Cell Therapy Group
Shanghai Cell Therapy Group is a company based in Shanghai (China) founded in 2014. Shanghai Cell Therapy Group has raised $201.91 million across 4 funding rounds from investors including China Pacific Insurance, China Asset Management and Jiuzhou Venture Capital. Shanghai Cell Therapy Group operates in a competitive market with competitors including Blue Rock Therapeutics, CellCarta, Ascend, Impel Pharmaceuticals and RiboPro, among others.
- Headquarter Shanghai, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$201.91 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
China Pacific Insurance
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Shanghai Cell Therapy Group
Shanghai Cell Therapy Group has successfully raised a total of $201.91M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Shanghai Cell Therapy Group
Shanghai Cell Therapy Group has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include China Pacific Insurance, China Asset Management and Jiuzhou Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Shanghai Cell Therapy Group
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Shanghai Cell Therapy Group
Investment portfolio details for Shanghai Cell Therapy Group
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Shanghai Cell Therapy Group
Detailed financials for Shanghai Cell Therapy Group
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Shanghai Cell Therapy Group Comparisons
Peer comparison for Shanghai Cell Therapy Group
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Shanghai Cell Therapy Group
Shanghai Cell Therapy Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Blue Rock Therapeutics, CellCarta, Ascend, Impel Pharmaceuticals and RiboPro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| Locked | Locked | Locked |
Histopathology and genomics services are offered by the CRO.
|
|
| Locked | Locked | Locked |
Online insurance payments and premium financing are enabled for businesses.
|
|
| Locked | Locked | Locked |
Transformative therapies are developed and commercialized through specialized services.
|
|
| Locked | Locked | Locked |
Online supplier and developer of RNA based products
|
Detailed competitors of Shanghai Cell Therapy Group
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Shanghai Cell Therapy Group
Complete news archive for Shanghai Cell Therapy Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shanghai Cell Therapy Group
Shanghai Cell Therapy Group was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Shanghai Cell Therapy Group is headquartered in Shanghai, China.
Shanghai Cell Therapy Group is a funded company, having raised a total of $201.91M across 4 funding rounds to date.
Shanghai Cell Therapy Group was founded in 2014 and is based in Shanghai, China. Operations are focused on the biotechnology sector, with services centered on research and development for cell therapies. Expertise is applied to various stages of cell-based treatment development, including preclinical studies and innovation support. The company serves clients in the medical and pharmaceutical fields through tailored RD solutions in this specialized domain.
Shanghai Cell Therapy Group's top competitors include Blue Rock Therapeutics, Ascend and CellCarta.
Shanghai Cell Therapy Group has 7 investors. Key investors include China Pacific Insurance, China Asset Management, Jiuzhou Venture Capital, CCB International, and Haier Capital.